-
Brazil's 'action agenda' at COP30 takes shape
-
Trump threatens $1 billion action as BBC apologises for edit error
-
Sinner dominates injury-hit Auger-Aliassime in ATP Finals opener
-
Trump hails Syria's 'tough' ex-jihadist president after historic talks
-
Syria's ex-jihadist president meets Trump for historic talks
-
Top US court hears case of Rastafarian whose hair was cut in prison
-
US mediator Kushner and Netanyahu discuss phase two of Gaza truce
-
End to US government shutdown in sight as Democrats quarrel
-
Trump threatens air traffic controllers over shutdown absences
-
US to remove warnings from menopause hormone therapy
-
UK water firm says 'highly likely' behind plastic pellet pollution incident
-
Syria's ex-jihadist president holds historic Trump talks
-
End to record-long US government shutdown in sight
-
France's ex-leader Sarkozy says after jail release 'truth will prevail'
-
Atalanta sack coach Juric after poor start to season
-
Trump threatens $1 billion action as BBC apologises for speech edit
-
Gattuso wants 'maximum commitment' as Italy's World Cup bid on the line
-
Indian capital car blast kills at least eight
-
Deadly measles surge sees Canada lose eradicated status
-
Brazil's Lula urges 'defeat' of climate deniers as COP30 opens
-
Strangled by jihadist blockade, Malians flee their desert town
-
US Supreme Court declines to hear case challenging same-sex marriage
-
'Fired-up' Fritz sees off Musetti in ATP Finals
-
Injured Courtois set to miss Belgium World Cup qualifiers
-
Bulatov, pillar of Russian contemporary art scene, dies at 92
-
Fritz sees off Musetti in ATP Finals
-
US strikes on alleged drug boats kill six more people
-
Sarkozy released from jail 'nightmare' pending appeal trial
-
COP30 has a mascot: the fiery-haired guardian of Brazil's forest
-
The Sudanese who told the world what happened in El-Fasher
-
Three things we learned from the Sao Paulo Grand Prix
-
ASC acquire majority share in Atletico Madrid
-
Ferrari boss tells Hamilton, Leclerc to drive, not talk
-
Bank of England seeks to 'build trust' in stablecoins
-
China suspends 'special port fees' on US vessels for one year
-
French court frees ex-president Sarkozy from jail pending appeal
-
No link between paracetamol and autism, major review finds
-
Typhoon Fung-wong floods Philippine towns, leaves 5 dead in its wake
-
France's Sarkozy says prison a 'nightmare' as prosecutors seek his release
-
Guinness maker Diageo picks new CEO after US tariffs cloud
-
China suspends 'special port fees' on US vessels
-
US senators take major step toward ending record shutdown
-
Typhoon Fung-wong leaves flooded Philippine towns in its wake
-
From Club Med to Beverly Hills: Assinie, the Ivorian Riviera
-
The 'ordinary' Arnie? Glen Powell reboots 'The Running Man'
-
Typhoon exposes centuries-old shipwreck off Vietnam port
-
French court to decide if ex-president Sarkozy can leave jail
-
China lifts sanctions on US units of South Korea ship giant Hanwha
-
Japan death row inmate's sister still fighting, even after release
-
Taylor sparks Colts to Berlin win as Pats streak hits seven
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN